EUCTR2015-002855-85-LT进行中（未招募）1 期
A randomized phase II multicenter study to assess the tolerability andefficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCTCI= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patientsaged >=66 years.A study in the frame of the masterprotocol of parallel randomized phase IIstudies in UNFIT-older AML/high-risk MDS patients. - HOVON 135 AML /SAKK 30/15
HOVON Foundation0 个研究点目标入组 170 人开始时间: 2017年4月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with:
- •-a diagnosis of AML and related precursor neoplasms according to WHO
- •2008 classification (excluding acute promyelocytic leukemia) including
- •secondary AML (after an antecedent hematological disease (e.g. MDS)
- •and therapy-related AML, or
- •-acute leukemia's of ambiguous lineage according to WHO 2008 or
- •-a diagnosis of refractory anemia with excess of blasts (MDS) and
- •IPSS-R > 4.5
- •Patients 66 years and older.
- •Patients NOT eligible for standard chemotherapy, defined as HCT-CI =
- •Patient NOT eligible for standard chemotherapy for other reasons
- •(wish of patient).
- •WBC = 30 x109/L (prior hydroxyurea allowed for a maximum of 5
- •days, stop 2 days before start decitabine treatment)
- •Adequate renal and hepatic functions unless clearly disease related as
- •indicated by the following laboratory values:
- •- Serum creatinine = 2.5 mg/dL (= 221.7 µmol/L), unless considered
- •AML-related
- •- Serum bilirubin = 2.5 x upper limit of normal (ULN), unless considered
- •AML-related or due to Gilbert's syndrome
- •- Alanine transaminase (ALT) = 2.5 x ULN, unless considered AMLrelated
- •WHO performance status 0, 1 or 2 (see Appendix D).
- •Male patients must use an effective contraceptive method during the
- •study and for a minimum of 6 months after study treatment.
- •Written informed consent.
- •Patient is capable of giving informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •Acute promyelocytic leukemia.
- •Patients previously treated for AML (any antileukemic therapy
- •including investigational agents), a short treatment period ( = 5 days)
- •with Hydroxyurea is allowed
- •Diagnosis of any previous or concomitant malignancy is an exclusion
- •criterion: except when the patient completed successfully treatment
- •(chemotherapy and/or surgery and/or radiotherapy) with curative
- •intent for this malignancy at least 6 months prior to randomization.
- •Blast crisis of chronic myeloid leukemia.
- •Inability to discontinue anti-coagulants
- •Concurrent severe and/or uncontrolled medical condition (e.g.
- •uncontrolled diabetes, infection, hypertension, pulmonary disease etc.)
- •Cardiac dysfunction as defined by:
- •- Myocardial infarction within the last 3 months of study entry, or
- •- Reduced left ventricular function with an ejection fraction < 40% as
- •measured by MUGA scan or echocardiogram or
- •- Unstable angina or
- •- New York Heart Association (NYHA) grade IV congestive heart failure
- •- Unstable cardiac arrhythmias
- •Patient has had major surgery within the past 4 weeks or a major
- •wound that has not fully healed.
- •Vaccinated with live, attenuated vaccines within 4 weeks prior to
- •randomization.
- •History of stroke or intracranial hemorrhage within 6 months prior to
- •randomization.
- •Patient has a history of human immunodeficiency virus (HIV) or active
- •XML File Identifier: SXmsnkJS62Kp3K7o0KPX0ptFWus=
- •infection with Hepatitis C or B.
- •Patient has symptomatic central nervous system (CNS) leukemia (NO
- •routinely lumbar puncture required to investigate CNS involvement)
- •Patients with a history of non-compliance to medical regimens or who
- •are considered unreliable with respect to compliance.
- •Patients with any serious concomitant medical condition which could,
- •in the opinion of the investigator, compromise participation in the study.
- •Patients who have senile dementia, mental impairment or any other
- •psychiatric disorder that prohibits the patient from understanding and
- •giving informed consent.
- •Current concomitant chemotherapy, radiation therapy, or
- •immunotherapy; other than hydroxyurea
- •Any psychological, familial, sociological or geographical condition
- •potentially hampering compliance with the study protocol and follow-up
研究者
相似试验
尚未招募
2 期
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patientsmyelodysplastic syndromes10024324Acute myeloid leukemiaNL-OMON53140HOVO70
进行中（未招募）
1 期
A randomized study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy. ,EUCTR2018-000047-31-NLHOVON Foundation140
已完成
2 期
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.myelodysplastic syndromes10024324Acute myeloid leukemiaNL-OMON55438HOVO88
进行中（未招募）
1 期
A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.Acute Meyloid Leukemia and High Risk Myelodysplastic syndromesMedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002855-85-BEHOVON Foundation170
进行中（未招募）
1 期
A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.Acute Meyloid Leukemia and High Risk Myelodysplastic syndromesMedDRA version: 19.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002855-85-NLHOVON Foundation170